API Predominant product Imatinib Mesylate CAS NO.220127-57-1

Predominant product - Imatinib mesylate can inhibit Bcr-Abl tyrosine kinase at the cell level in vitro and in vivo, and can selectively inhibit the proliferation and apoptosis of fresh cells of Bcr-Abl positive cell line cells, Ph chromosome positive chronic myelocytic leukemia and acute lymphoblastic leukemia patients. In addition, imatinib mesylate can also inhibit the platelet derived growth factor (PDGF) receptor, stem cell factor (SCF), and tyrosine kinase of the c-Kit receptor, thus inhibiting the cell behavior mediated by PDGF and stem cell factors.

Patients with chronic myelocytic leukemia (CML) were treated for a chronic period of sudden change, acceleration, or alpha interferon, and patients with malignant gastrointestinal stromal tumors (GIST) that were not excised or transferred.

 Imatinib mesylate can inhibit Bcr-Abl tyrosine kinase at the cell level in vitro and in vivo, and can selectively inhibit the proliferation and apoptosis of fresh cells of Bcr-Abl positive cell line cells, Ph chromosome positive chronic myelocytic leukemia and acute lymphoblastic leukemia patients. In addition, imatinib mesylate can also inhibit the platelet derived growth factor (PDGF) receptor, stem cell factor (SCF), and tyrosine kinase of the c-Kit receptor, thus inhibiting the cell behavior mediated by PDGF and stem cell factors.

Patients with chronic myelocytic leukemia (CML) were treated for a chronic period of sudden change, acceleration, or alpha interferon, and patients with malignant gastrointestinal stromal tumors (GIST) that were not excised or transferred.